Skip to main content
x

Recent articles

Amgen looks for Five Prime payback

A key pivotal study of bemarituzumab will read out shortly.

Yet more conjugates enter the clinic

Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.

Chimerix's cancer transformation

US approval could mark the company's graduation to oncology.

Boehringer beats Bayer to the regulators

The FDA will rule on a low dose of zongertinib in the summer.

ASCO-GU – another strike against Cabometyx

A triplet did worse than control in first-line kidney cancer.

Kyowa joins GSK in Tim-3

Meanwhile, Tango tries again in PRMT5.